Dementia News recently attended the 9th Alzheimer’s + Parkinson’s Disease (A+PD) Symposium hosted by The Queensland Brain Institute, University of Queensland and has written about the challenges of research and why we need to think twice about ‘breakthrough mice studies’ following a keynote address by Professor Frank LaFerla.
Director of Institute for Memory Impairments and Neurological Disorders at the University of California Irvine, Professor Frank LaFerla’s keynote address focussed on the challenges of translating results from Alzheimer’s disease mouse studies into human clinical trials.
Professor LaFerla pointed out that mice have been used as an animal subject for Alzheimer’s disease trials since the 1980’s however, no new treatments for Alzheimer’s disease have been approved for use. The only two currently approved treatments, acetylcholinesterase inhibitors and memantine, which are used to reduce the severity of some Alzheimer’s disease symptoms, were not tested in mice prior to their testing in humans.
So why has such little progress been made, why do we rarely see mice studies translate into human results and what is the future for mice studies in Alzheimer’s disease?
To find out Professor LaFerla’s thoughts visit: Dementia News.